ACTIVE

KiOmed Pharma

Export PDF

Financial year 2025 · Closed on 31/12/2025

Net result
2,2 M €
+173,3 %over 1 year
Gross margin
8 M €
+169,3 %over 1 year
Equity
9 M €
+107,3 %over 1 year
Workforce
30,2 ETP
-8,5 %over 1 year

Identity

Source · BCE/KBO

KiOmed Pharma is a Public limited company incorporated in 2012. Its main activity is: Research and experimental development on natural sciences and engineering. Its registered office is in Herstal. It employs on average 30,2 ETP workers (FTE).

Legal situation
Normal situation
BCE/KBO no. / VAT
BE 0846.318.862
Incorporation
04/06/2012
Legal form
Public limited company
Registered office
Rue Haute Claire 4
4041 Herstal · WallonieSee on map
Contributed capital
11 651 663,28 €
Latest accounts
31/12/2025
Average workforce
30,2 ETP
Signals
ProfitableSolid equityPositive cashflowPositive EBITDAHealthy social debts

Financials

Source · NBB, 14 filings

Trend over 13 financial years

20252024202320222021
Income statement
Gross margin8 M €3 M €-767,3 k €–3,7 M €
EBITDA4,7 M €-411,2 k €-3,4 M €4,5 M €2,3 M €
Operating result365,7 k €-4,4 M €-6,4 M €1,9 M €-185,4 k €
Net result2,2 M €-3 M €-5,1 M €3 M €845,8 k €
Balance sheet
Equity9 M €4,4 M €5,3 M €9,2 M €5,9 M €
Total assets19,7 M €22,7 M €18,9 M €15,3 M €14,2 M €
Cash257,1 k €1,2 M €982,2 k €1,7 M €2,9 M €
Debts10,6 M €18,3 M €13,6 M €6,1 M €8,3 M €
Other
Workforce30,2 ETP33,0 ETP29,2 ETP19,6 ETP15,6 ETP

Valuation

Indicative valuation

As an indication, this company is worth

between 5 M€ and 10 M€
See the valuation

Board of directors

Source · NBB, accounts to 31/12/2025

8 active · 45 ended

Active mandates

CHAGRAL INVEST

Mandate · 0668.490.049

Represented by Marc NOLET DE BRAUWERE

Active
CLARENTIS

Mandate · 0740.928.560

Represented by Antony BLANC

Active
GRAINN

Mandate · 0535.993.987

Represented by Houtaï CHOUMANE

Active
INNODE

Mandate · 0465.880.805

Represented by François BLONDEL

Active
KITOZYME

Mandate · 0473.676.932

Represented by Marie HOBE

Active
NOSHAQ PARTNERS

Mandate · 0808.219.836

Represented by Benoît FELLIN

Active
SPARAXIS

Mandate · 0452.116.307

Represented by Caroline THIELEN

Active
VALOIS

Mandate · 0402.251.773

Represented by Carl MESTDAGH

Active

Ended mandates

VALOIS

Director · since 18 mars 2025 · until 29 mai 2031 · 0402.251.773

Represented by Carl MESTDAGH

Ended
SPARAXIS

Director · since 30 mai 2024 · until 18 mars 2025 · 0452.116.307

Ended
Pierre RIGAUX

Director · since 27 septembre 2019 · until 26 septembre 2020

Ended
Pierre RIGAUX

Director · since 27 septembre 2019 · until 27 mai 2021

Ended

Full financial information

Source · NBB
202520242023202220212020
Type of accountAbridged modelAbridged modelAbridged modelFull modelAbridged modelAbridged model
Start of the financial year01/01/202501/01/202401/01/202301/01/202201/01/202101/01/2020
Closing of the financial year31/12/202531/12/202431/12/202331/12/202231/12/202131/12/2020
Length of the financial year12 months12 months12 months12 months12 months12 months
Filing date02/06/202620/06/202505/06/202409/06/202322/06/202223/07/2021
General meeting28/05/202630/05/202530/05/202425/05/202326/05/202227/05/2021
Currency of the financial yearEUREUREUREUREUREUR
NBB quality labelSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controlsSatisfying controls

Financial ratios

Source · NBB

Looking for more information about this company?

Try for 7 days

Annual accounts filings

Source · NBB, 14 filings
ModelClosingGeneral meetingFiledLanguageDocument
Abridged model31/12/202528/05/202602/06/2026FrenchPDF
Abridged model31/12/202430/05/202520/06/2025FrenchPDF
Abridged model31/12/202330/05/202405/06/2024FrenchPDF
Full model31/12/202225/05/202309/06/2023FrenchPDF
Abridged model31/12/202126/05/202222/06/2022FrenchPDF
Abridged model31/12/202027/05/202123/07/2021FrenchPDF
Abridged model31/12/201928/05/202010/07/2020FrenchPDF
Abridged model31/12/201829/05/201925/06/2019FrenchPDF
Abridged model31/12/201731/05/201820/06/2018FrenchPDF
Abridged model31/12/201626/05/201706/07/2017FrenchPDF
Abridged modelCorrection31/12/201526/05/201606/09/2016FrenchPDF
Abridged model31/12/201526/05/201610/08/2016FrenchPDF
Abridged model31/12/201424/06/201513/07/2015FrenchPDF
Abridged model31/12/201330/05/201426/06/2014FrenchPDF

Indicative valuation

Order of magnitude

As an indication, this company is worth

between 5 M€ and 10 M€

The detail comes with the Business plan: low and high bounds, the valuation bridge for each financial year, transaction multiples by sector and size, group valuation and exports.

Discover the Business plan
Disclaimer

Indicative estimate based on public sector multiples and the filed annual accounts. It is neither a certified valuation nor financial or investment advice.

Board of directors

Source · NBB, accounts to 31/12/2025

8 active · 45 ended

Active mandates

CHAGRAL INVEST

Mandate · 0668.490.049

Represented by Marc NOLET DE BRAUWERE

Active
CLARENTIS

Mandate · 0740.928.560

Represented by Antony BLANC

Active
GRAINN

Mandate · 0535.993.987

Represented by Houtaï CHOUMANE

Active
INNODE

Mandate · 0465.880.805

Represented by François BLONDEL

Active
KITOZYME

Mandate · 0473.676.932

Represented by Marie HOBE

Active
NOSHAQ PARTNERS

Mandate · 0808.219.836

Represented by Benoît FELLIN

Active
SPARAXIS

Mandate · 0452.116.307

Represented by Caroline THIELEN

Active
VALOIS

Mandate · 0402.251.773

Represented by Carl MESTDAGH

Active

Ended mandates

VALOIS

Director · since 18 mars 2025 · until 29 mai 2031 · 0402.251.773

Represented by Carl MESTDAGH

Ended
SPARAXIS

Director · since 30 mai 2024 · until 18 mars 2025 · 0452.116.307

Ended
Pierre RIGAUX

Director · since 27 septembre 2019 · until 26 septembre 2020

Ended
Pierre RIGAUX

Director · since 27 septembre 2019 · until 27 mai 2021

Ended

Ownership and network

Looking for more information about this company?

Try for 7 days

Belgian Official Gazette publications

Source · Belgian Official Gazette
  • Other01/09/2026
    Renouvellement de mandats
    PDF
  • Capital / shares15/07/2026
    CAPITAL, ACTIONS
    PDF
  • Mandates25/09/2025
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates31/03/2025
    CAPITAL, ACTIONS - DEMISSIONS, NOMINATIONS
    PDF
  • Capital / shares16/01/2025
    STATUTS (TRADUCTION, COORDINATION, AUTRES MODIFICATIONS, …) - CAPITAL, ACTIONS
    PDF
  • Mandates13/09/2024
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates16/08/2023
    DEMISSIONS, NOMINATIONS
    PDF
  • Mandates01/06/2023
    DEMISSIONS, NOMINATIONS
    PDF

Similar companies

A company's peers, by sector and size, are included in the Business plan.

See the Business plan

Timeline

  1. 2025
    Annual accounts 20252,2 M €↑
  2. 2024
    Annual accounts 2024-3 M €↑
  3. 2023
    Annual accounts 2023-5,1 M €↓
  4. 2022
    Annual accounts 20223 M €↑
  5. 2021
    Annual accounts 2021845,8 k €↑
  6. 2020
    Annual accounts 2020-2,8 M €↓
  7. 2019
    Annual accounts 2019-2,5 M €↓
  8. 2018
    Annual accounts 2018-1,9 M €↑
  9. 2017
    Annual accounts 2017-1,9 M €↓
  10. 2016
    Annual accounts 2016-1,6 M €↓
  11. 2015
    Annual accounts 2015-895,1 k €↑
  12. 2014
    Annual accounts 2014-1,1 M €↓
  13. 2013
    Annual accounts 2013-341,6 k €
  14. 04/06/2012
    IncorporationPublic limited company